Last reviewed · How we verify
Fluad Vaccine — Competitive Intelligence Brief
marketed
Inactivated influenza vaccine with adjuvant
Immunology / Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Fluad Vaccine (Fluad Vaccine) — David H. Canaday. Fluad is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluad Vaccine TARGET | Fluad Vaccine | David H. Canaday | marketed | Inactivated influenza vaccine with adjuvant | ||
| Fluad alone | Fluad alone | Korea University Guro Hospital | marketed | Inactivated influenza vaccine with adjuvant | Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Inactivated influenza vaccine with adjuvant class)
- David H. Canaday · 1 drug in this class
- Korea University Guro Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluad Vaccine CI watch — RSS
- Fluad Vaccine CI watch — Atom
- Fluad Vaccine CI watch — JSON
- Fluad Vaccine alone — RSS
- Whole Inactivated influenza vaccine with adjuvant class — RSS
Cite this brief
Drug Landscape (2026). Fluad Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluad-vaccine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing